BC Extra | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

A series of follow-ons pushed biotechs to raise about $1.5 billion this week, bringing January's total raise to about $2.6 billion via 16 follow-ons. The offerings have already outpaced last January, which saw $1.7 billion...
BC Extra | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...
BC Extra | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold  FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BC Extra | Oct 15, 2019
Politics & Policy

Protests delay Hong Kong biotech conference

In the latest blow to the Hong Kong biotech community caused by ongoing regional protests, the 2020 Hong Kong biotech convention BIOHK2020 has been postponed. The announcement cited the unpredictable situation and concern for the...
BC Extra | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to list on the exchange’s biotech chapter in four months Wednesday, raising HK$3.2 billion ($409.9 million) in an IPO that...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
Items per page:
1 - 10 of 167
BC Extra | Jan 24, 2020
Financial News

January fund-raising sets pace with $2.6B in follow-ons

A series of follow-ons pushed biotechs to raise about $1.5 billion this week, bringing January's total raise to about $2.6 billion via 16 follow-ons. The offerings have already outpaced last January, which saw $1.7 billion...
BC Extra | Jan 22, 2020
Company News

Jan. 21 Company Quick Takes: First BCMA-targeted therapy gets Priority Review from FDA; plus Roche-Seattle Genetics, AZ-Merck, Chi-Med

Priority Review for GSK's anti-BCMA therapy in MM  GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said FDA granted Priority Review to a BLA for belantamab mafodotin to treat fourth-line relapsed or refractory multiple myeloma in patients who have...
BC Extra | Dec 13, 2019
Financial News

First day gains for Alphamab Oncology reflect Hong Kong exchange’s growing momentum

Double digit gains by Alphamab Oncology are the latest sign that Hong Kong’s biotech chapter has shrugged off mid-year doldrums and uncertainty caused by ongoing protests. Alphamab Oncology Ltd. (HKEX:9966) rose HK$3.30 (32%) to HK$13.50...
BC Extra | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

The widely anticipated release of negotiated additions to the National Reimbursement Drug List by China’s National Medical Insurance Administration came on Nov. 28, with Innovent’s Tyvyt the lone anti-PD-1 mAb to make the cut. In...
BC Extra | Nov 13, 2019
Company News

Nov. 12 Company Quick Takes: Clinical hold for Solid Bio; plus Foamix-Menlo, Chi-Med, RegeneRx and Actelion

Solid Bio shares sag on news of latest clinical hold  FDA has placed a clinical hold on the Phase I/II IGNITE DMD study of gene therapy SGT-001 from Solid Biosciences Inc. (NASDAQ:SLDB) after one of...
BC Extra | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BC Extra | Oct 15, 2019
Politics & Policy

Protests delay Hong Kong biotech conference

In the latest blow to the Hong Kong biotech community caused by ongoing regional protests, the 2020 Hong Kong biotech convention BIOHK2020 has been postponed. The announcement cited the unpredictable situation and concern for the...
BC Extra | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to list on the exchange’s biotech chapter in four months Wednesday, raising HK$3.2 billion ($409.9 million) in an IPO that...
BioCentury | Aug 12, 2019
Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
BC Extra | Jul 31, 2019
Company News

July 30 Company Quick Takes: Gilead beats on revenues with the help of Biktarvy, Yescarta; plus Pfizer and Ligand

Biktarvy, Yescarta beat estimates  Gilead Sciences Inc. (NASDAQ:GILD) raised its 2019 sales guidance after reporting higher-than-expected 2Q19 earnings driven by sales of HIV drug Biktarvy bictegravir/emtricitabine/tenofovir alafenamide and CAR T therapy Yescarta axicabtagene ciloleucel. Biktarvy...
Items per page:
1 - 10 of 167